Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Celgene will pay AstraZeneca $450 million to participate in development of MEDI4736, an anti-PD-L1 inhibitor for hematologic malignancies. The pact will focus on combining the AstraZeneca antibody with products in Celgene’s pipeline. Separately, Celgene has paid Northern Biologics, a biotech firm backed by Versant Ventures, $30 million for rights to license oncology antibodies in Northern’s pipeline and to acquire Northern. And Celgene has paid Agios Pharmaceuticals $10 million to expand an earlier pact to develop AG-881, a small molecule in development to treat brain cancer.
This article has been sent to the following recipient: